Shots:
- Ocugen has entered into a licensing agreement with Kwangdong Pharmaceutical for OCU400 to treat retinitis pigmentosa
- As per the deal, Kwangdong will receive exclusive Korean rights to OCU400 in exchange for $7.5M in upfront & near-term milestones, $1.5M per $15M in sales, reaching ≥$180M in sales milestones, plus 25% royalties on net sales, while Ocugen handles manufacturing of the commercial supply
- OCU400 will advance into P-III trials, targeting a US FDA’s BLA submission in 2026, & Kwangdong plans to leverage Ocugen’s clinical data & BLA filing for its regulatory approval process in Korea
Ref: Ocugen | Image: Ocugen & Kwangdong Pharmaceutical | Press Release
Related News:- Kashiv BioSciences Collaborates with CRISTÁLIA to Commercialize ADL-018 (Biosimilar, Xolair) in Latin America
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
